ZYCOS to Present Phase I/II Data on Lead DNA-based Drug at 5th International AIDS Malignancy Conference and 4th Annual Conference on Vaccine Research

- Results Demonstrate Potential of ZYCOS' Technologies

In Different Disease Areas -



Apr 19, 2001, 01:00 ET from ZYCOS INC.

    LEXINGTON, Mass., April 19 /PRNewswire/ -- ZYCOS INC., announced today
 that the company will present positive Phase I/II data on its lead product
 (ZYC101), designed to treat pre-cancerous infections caused by the human
 papillomavirus, at two upcoming conferences sponsored by the National Cancer
 Institute and the National Foundation for Infectious Diseases. ZYCOS
 scientists and one of its principal investigators will report on the safety
 and immunogenicity of ZYC101 in cervical dysplasia and anal dysplasia
 patients.
     At the NCI Fifth International AIDS Malignancy Conference taking place in
 Bethesda, MA on April 23rd, Dr. Barbara Klencke, M.D., University of
 California, San Francisco, and principal investigator for ZYCOS' Phase I/II
 study in anal dysplasia patients, will present "Results from a Phase I Trial
 of a Microsphere Encapsulated DNA Vaccine for High-grade Anal Dysplasia."
 Dr. Robert Urban, V.P. of New Technologies and Targets at ZYCOS will present
 "Immunization of HPV Positive Patients with High-grade Cervical Dysplasia
 Using a Microsphere Encapsulated DNA Vaccine:  Results in HPV Specific Immune
 Responses" during a round table discussion on HPV vaccines.
     ZYCOS will also attend the NFID Fourth Annual Vaccine Research Conference
 being in Arlington, VA from April 23rd - 25th, to present the immunological
 data from the Phase I/II study in anal dysplasia patients.
     "We are excited by the progress our ZYC101 program has made. These studies
 confirm that ZYCOS' microsphere encapsulated DNA technology has broad
 potential to treat several diseases," said Mark Philip, CEO of ZYCOS. "We are
 pursuing an aggressive development plan to bring several other products based
 on this novel technology to the clinic."
     ZYCOS is currently in a multinational Phase II clinical study with ZYC101a
 for the treatment of cervical dysplasia. The Company also has product
 candidates in preclinical development for the treatment of cancer and
 inflammatory conditions.
 
     ZYCOS (http://www.zycos.com) is a privately held company located in
 Lexington, Massachusetts. ZYCOS' core technology platform has led to the
 development of a new category of therapeutic medicines targeting multi-billion
 dollar markets in the areas of cancer, viral infections and autoimmune
 disease. ZYCOS' discovery technology enables the rapid discovery of
 disease-specific antigens. The company has also developed novel systems for
 DNA expression and DNA drug delivery. ZYCOS' first product candidate, ZYC101a
 is designed to treat cervical infections associated with the human
 papillomavirus and is currently in Phase II clinical studies.
 
     Editor's Note: The National Cancer Institute issued a Consensus Statement
 in 1996 (http://www.consensus.nih.gov) which stressed the medical need for a
 non-surgical immunological approach to manage cervical disease.
 
     Contacts:
 
     Melissa Chen                             Renee Connolly
     Business Development Executive           Noonan/Russo Communications
     781-274-6500 x211                        212-696-4455 ext. 227
     mchen@zycos.com                          renee@noonanrusso.com
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X31764664
 
 

SOURCE ZYCOS INC.
    LEXINGTON, Mass., April 19 /PRNewswire/ -- ZYCOS INC., announced today
 that the company will present positive Phase I/II data on its lead product
 (ZYC101), designed to treat pre-cancerous infections caused by the human
 papillomavirus, at two upcoming conferences sponsored by the National Cancer
 Institute and the National Foundation for Infectious Diseases. ZYCOS
 scientists and one of its principal investigators will report on the safety
 and immunogenicity of ZYC101 in cervical dysplasia and anal dysplasia
 patients.
     At the NCI Fifth International AIDS Malignancy Conference taking place in
 Bethesda, MA on April 23rd, Dr. Barbara Klencke, M.D., University of
 California, San Francisco, and principal investigator for ZYCOS' Phase I/II
 study in anal dysplasia patients, will present "Results from a Phase I Trial
 of a Microsphere Encapsulated DNA Vaccine for High-grade Anal Dysplasia."
 Dr. Robert Urban, V.P. of New Technologies and Targets at ZYCOS will present
 "Immunization of HPV Positive Patients with High-grade Cervical Dysplasia
 Using a Microsphere Encapsulated DNA Vaccine:  Results in HPV Specific Immune
 Responses" during a round table discussion on HPV vaccines.
     ZYCOS will also attend the NFID Fourth Annual Vaccine Research Conference
 being in Arlington, VA from April 23rd - 25th, to present the immunological
 data from the Phase I/II study in anal dysplasia patients.
     "We are excited by the progress our ZYC101 program has made. These studies
 confirm that ZYCOS' microsphere encapsulated DNA technology has broad
 potential to treat several diseases," said Mark Philip, CEO of ZYCOS. "We are
 pursuing an aggressive development plan to bring several other products based
 on this novel technology to the clinic."
     ZYCOS is currently in a multinational Phase II clinical study with ZYC101a
 for the treatment of cervical dysplasia. The Company also has product
 candidates in preclinical development for the treatment of cancer and
 inflammatory conditions.
 
     ZYCOS (http://www.zycos.com) is a privately held company located in
 Lexington, Massachusetts. ZYCOS' core technology platform has led to the
 development of a new category of therapeutic medicines targeting multi-billion
 dollar markets in the areas of cancer, viral infections and autoimmune
 disease. ZYCOS' discovery technology enables the rapid discovery of
 disease-specific antigens. The company has also developed novel systems for
 DNA expression and DNA drug delivery. ZYCOS' first product candidate, ZYC101a
 is designed to treat cervical infections associated with the human
 papillomavirus and is currently in Phase II clinical studies.
 
     Editor's Note: The National Cancer Institute issued a Consensus Statement
 in 1996 (http://www.consensus.nih.gov) which stressed the medical need for a
 non-surgical immunological approach to manage cervical disease.
 
     Contacts:
 
     Melissa Chen                             Renee Connolly
     Business Development Executive           Noonan/Russo Communications
     781-274-6500 x211                        212-696-4455 ext. 227
     mchen@zycos.com                          renee@noonanrusso.com
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X31764664
 
 SOURCE  ZYCOS INC.